By CERBIOS-PHARMA SA
To get in touch with CERBIOS-PHARMA SA, simply fill out the form below.
Subscribe to Supplier
Cerbios-Pharma presents QbD approach to optimizing payloads at World ADC Europe 2022
Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) will again be a high profile presence at the World ADC Europe conference in London, presenting advanced fully integrated solutions antibody drug conjugates.
Cerbios will be represented along with its partners at the PROVEO booth in the exhibition zone, highlighting the work of its dedicated Proveo business division in providing one stop shop solutions for ADC development and manufacturing. Proveo is also a sponsor of the event.
Optimizing ADC payload
A strong theme of Cerbios contributions to the conference will be its experiences in the development and manufacturing of complex payload molecules and it will contribute to the scientific sessions with presentation of a case study on optimization of payload development and manufacturing.
Cerbios R&D Director Dr. Alberto Terraneo will present “Next generation linker-payloads development and manufacture: a CDMO witness” stressing the key role of the linker in ADC safety and efficacy.
As drug developers pursue new epitopes to enlarge the applicability of ADCs to new tumor classes, there is increasing focus on the linker – payload part of the ADC.
Dr. Terraneo argues that these technical issues, and the demanding timeframes of innovators to reach a successful Biologics License Application (BLA) requires a more modern approach to chemical process development, that stresses QbD methodology to prioritize the issues to address plus extensive use of preparative high-performance liquid chromatography (HPLC) as the principal control strategy, along with tangential flow filtration and lyophilization for recovery. “These are the keys to the successful development and production of the most recent linker-payloads”, he says.
Apart from Dr. Terraneo, Cerbios and Proveo team at ADC World Europe will include Cerbios-Pharma SA CDMO Business Development Manager Vítor Sousa, along with Christoph Winterhalter, Senior Vice President Business Development at AGC Biologics, and Matthias Beck, Manager New Business Development at the other Proveo partner, Oncotec Pharma Produktion GmbH.
Cerbios will host the Lunch and Seminar Session on Day One of the event that will involve key players in the ADC field. The company will also use this only-invitation event to share latest information about the building of its new HPAPI manufacturing facility.
Cerbios is a privately held company located in Lugano, Switzerland, specialized in manufacturing Pharma Products and in offering CDMO services.
Cerbios is a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders. Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response.
Cerbios is also the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, live Biotherapeutics, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Proveo (TM) is a Cerbios division recently created to provide end-to-end development and manufacturing services for ADCs.
Learn more at: https://cerbios.swiss
About World ADC Europe 2022
The World ADC Conference complements World ADC USA in forming is the industry’s longest standing and most comprehensive series of events devoted to Antibody Drug Conjugate technology and solutions.
The 12th World ADC Europe congress will be a four-day event hybrid digital and face-to-face event opening March 29th at the Novotel West Hotel in Hammersmith, London and hosted online. Negative lateral flow Covid-19 tests will be required for those attending in person.
The 2022 conference will feature more than 60 hours of content sessions spread across four scientific and industry streams and involving more than industry expert speakers discuss a wide range of topics in four conference streams: Translational and CMC tracks along with separate Discovery streams for Biology and Chemistry, allowing deeper dives into novel format ADCs, payloads, antibody engineering and new targets.
The Europe conference also features the recently added CMC Day focusing on scale up to commercial manufacturing.
The event is organized by Hanson Wade with more information at: https://worldadc-europe.com.
Click on Cerbios-Pharma at World ADC Europe 2022 for more information.